Transforming DVT Treatment Through Precision Drug Delivery
Addressing the root cause of Post-Thrombotic Syndrome with the first-ever targeted anti-inflammatory therapy
Traditional treatment
Only addresses blood flow
Risk of post-thrombotic syndrome after clot removal in DVT patients
Mercator solution
Targeted drug delivery tackles inflammation and prevents chronic disability
Risk of post-thrombotic syndrome after clot removal in DVT patients
The Opportunity
100K
Annual DVT Cases
$0B
Market Size
$0K+
per Procedure
Revolutionary technology
FDA-cleared Bullfrog® Platform
First-ever precision drug delivery system that
targets the root cause
of chronic DVT complications
Proven clinical results
80% reduction in PTS Syndrome
Phase 2 trials demonstrate transformational patient outcomes that could redefine standard of care
Market opportunity
5+ years expected market exclusivity
Category-creating solution in a $1.3B underserved market with zero direct competitors
Business model
High-margin – strategic exit by 2028
FDA-cleared platform with $3K+ per-procedure reimbursement post-approval
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.